Overview:
According to Centers for Disease Control and Prevention (CDC), Cytomegalovirus (CMV) is a common virus that infects people of all ages. Most CMV infections are opportunistic infections and can be observed in people with a weakened immune system and in babies infected before birth. Market experts suggest that, it is a common herpesvirus infection with a broad range of symptoms: from no symptoms to fever and fatigue to severe symptoms involving the eyes, brain, or other internal organs. CMV spreads very easily and infected people may shed the virus in their urine or saliva for months. The virus is also excreted in cervical mucus, semen, stool, and breast milk. Thus, the virus is spread through sexual and nonsexual contact. The drugs used to treat cytomegalovirus are antiviral drugs such as valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination. The several CMV infections caused due to CMV are retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others).
Increasing number of organ transplants is one of key factor assisting market growth, and prevalence of symptomatic CMV infections is common in HIV so prevalence of HIV also supports the growth. Ganciclovir and valganciclovir were observed as the two first line drugs prescribed for treating CMV infections.
The key factor responsible for growth of cytomegalovirus infection is increasing public awareness related to herpes virus infections which is fueling the diagnosis rate in North America and Europe. North America was observed as the largest market for cytomegalovirus infection treatment followed by Europe. Asia Pacific was anticipated to grow at a fastest CAGR during the forecast period 2016 to 2023. The key factors assisting the growth of Asia Pacific cytomegalovirus infection treatment market are the rising awareness associated with the rare diseases, developing healthcare infrastructure, high disposable income and government support for novel treatment against rare genetic diseases. In case of key players it was observed that Roche has a strong presence in the CMV market, Valcyte was the only branded product for the treatment of CMV infections by 2013. The company is still likely to maintain its competitive position even after Valcyte lost its market exclusivity in 2013 (US) and 2015 (Europe).
The global cytomegalovirus (CMV) infection treatment market is segmented on the following bases:
1. Type of Drugs
a. Valganciclovir
b. Ganciclovir
c. Cidofovir
d. Foscarnet
2. Type of CMV Infections
a. Retinitis
b. Pneumonia
c. Gastrointestinal Ulcers
d. Encephalitis
e. Others (Mouth Ulcers, Pharyngitis, etc.)
f. Pipeline Analysis (Phase I, Phase II and Phase III Clinical Trials)
3. Geography
a. North America
i. US
ii. Canada
b. Europe
i. UK
ii. Germany
iii. Rest of Europe
c. Asia-Pacific
i. Japan
ii. China
iii. Rest of APAC
d. Latin America
e. Middle East and Africa
Key Players Identified for cytomegalovirus (CMV) infection Treatment Market Include but are Not Limited to:
The key players in the market are F. Hoffmann-La Roche, GlaxoSmithKline plc, Vical, Inc., AiCuris Anti-infective Cures GmbH, ViroPharma, Chimerix, Inc., and others.
This report offers:
